Title of cohort

    Maastricht Aging Study

    Acronym for cohort

    MAAS

    Name of Principal Investigator - Title

    Dr

    Name of Principal Investigator - First name

    Martin PJ

    Name of Principal Investigator - Last name

    van Boxtel

    Address of institution -Institution

    Maastricht University, Dept. Psychiatry & Neuropsychology

    Address of institution - Street address

    PO Box 616

    Address of institution - City

    Maastricht

    Address of institution - Postcode

    6200MD

    Country

    Netherlands

    Website
    Contact email
    Funding source

    Maastricht University

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias

    Q1b. When are studies on the above condition(s) expected to become possible?

    Already possible

    Q2a. In a single sentence what is the stated aim of the cohort?

    Study of normal cognitive aging and the effect of biomedical and psychosocial risk and protective factors

    Q2b. What distinguishes this cohort from other population cohorts?

    Wide age range (24-81 years at baseline, stratified by age group, general ability and sex)

    Q3a. i) Number of publications that involve use of your cohort to date

    135

    Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    See study website

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    24

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    81

    Q4b. Study criteria: what are the inclusion criteria?

    Gerontologically healthy

    Q4c. Study criteria: what are the exclusion criteria?

    no disease of central nervous system

    Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

    1,000-5,000 participants

    Q6a. Please describe what measures are used to characterise participants

    standard medical and cognitive tests

    Q6b. Are there additional measures for participants with a clinical disorder?

    at risk participants were additionally screened for cognitive disorders using CAMCOG

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    No

    If yes please specify

    Q7. What is the study design (select all that apply)?

    Prospective cohort| Cross-sectional| Longitudinal

    Q8. Are your cases matched by

    Q9a. Does your study include a specialised subset of control participants?

    No

    Q9b. If your study includes a specialised subset of control participants please describe

    Q10a. i) Please enter the data collection start date

    22/03/1993

    Q10a. ii) Please enter the data collection end date

    21/07/2007

    Q10a. iii) Is data collection for this study

    Data analysis ongoing| Closed to new patients

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - intend to apply for funding

    Q11. Is data collected

    Only through the study

    Other please specify here

    Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

    Yes (participants given permission to be re-contacted via PIs)

    Q13a. Please give information on the format and availability of data stored in a database (1)

    Data summarised in database

    % available

    100

    Q13a. Please give information on the format and availability of data stored in a database (2)

    No

    % available

    Q13a. Please give information on the format and availability of data stored in a database (3)

    No

    % available

    Q13a. Please give information on the format and availability of data stored in a database (4)

    No

    % available

    Other (please specify)

    Yes (not specified)

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (1)

    Data is held as individual records

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (2)

    No

    % available

    Q13b. Please give information on the format and availability of data held as individual records (3)

    Data held on computer based records

    % available

    100

    Q13b. Please give information on the format and availability of data held as individual records (4)

    No

    % available

    Please specify language used

    Dutch and English

    Q14a. Is data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Apply to PI or co-ordinator at resource| Access through collaboration with PI only| Access restricted to peer-reviewed work| Completion of research agreement on data use

    Q15. What data sharing policy is specified as a condition of use?

    Data made publicly available after a specified time point

    Q16a. Are tissues/samples/DNA available to other groups?

    No

    Q16b i) If yes, please describe below:

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Q17. Is information on biological characteristics available to other groups?

    Number of Patients

    % of total cohort

Types: Population Cohorts
Member States: Netherlands
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF